Apolipoprotein A-I Infusions and Cardiovascular Outcomes in Acute Myocardial Infarction According to Baseline LDL-Cholesterol Levels: The AEGIS-II Trial.
Charles Michael GibsonDanielle DuffyM Cecilia BahitGerald ChiHarvey D WhiteSerge KorjianJohn H AlexanderA Michael LincoffMark HeiseBronwyn A KingwellJose C NicolauRenato D LopesJan H CornelBasil S LewisDragos VinereanuShaun G GoodmanChristoph BodePh Gabriel StegPeter LibbyFrank M SacksKevin R BaineyPaul M RidkerKenneth W MahaffeyPhilip AylwardStephen J NichollsStuart J PocockRoxana MehranRobert A Harringtonnull nullPublished in: European heart journal (2024)
In this population, treatment with CSL112 compared to placebo was associated with a significantly lower risk of recurrent cardiovascular events among patients with a baseline LDL-C ≥100 mg/dL. Further studies need to confirm that CSL112 efficacy is influenced by baseline LDL-C.